/MEIP

MEIP Stock - MEI Pharma, Inc.

Q: What is the analyst price target for MEIP?

Analyst price target information is not currently available for MEIP.

Q: What is MEIP's market cap?

Market capitalization information is not currently available for MEIP.

Healthcare|Biotechnology|NASDAQ

$3.07+10.43%

+$0.29 (+10.43%) • Sep 10

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.38

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MEIP

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.22

52W High$9.00

52W Low$1.46

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	$65.30M	$48.82M	$40.70M	$25.54M
Gross Profit	N/A	$64.91M	$47.00M	$40.70M	$24.13M
Gross Margin	N/A	99.4%	96.3%	100.0%	94.5%
Operating Income	$-17,455,000	$14.54M	$-36,764,000	$-75,484,000	$-60,424,000
Net Income	$-15,945,000	$17.78M	$-31,840,000	$-54,450,000	$-41,310,000
Net Margin	N/A	27.2%	-65.2%	-133.8%	-161.8%
EPS	$-2.39	$2.67	$-4.78	$-8.75	$-7.34

Company Overview

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish1 Neutral/Bearish

Price Targets

No price targets available

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 23rd 2024	Laidlaw	Downgrade	Hold	-

Earnings History & Surprises

MEIP

Beat Rate

67%

Last 15 quarters

Avg Surprise

+58.7%

EPS vs Estimate

Beats / Misses

10/2

3 met exactly

Latest EPS

$-0.12

Q4 2025

EPS Surprise History

Q1 24

-13.7%

$-1.66vs$-1.46

Q2 24

+0.7%

$-1.37vs$-1.38

Q3 24

+23.6%

$-1.13vs$-1.48

Q4 24

+29.4%

$-1.20vs$-1.70

Q1 25

+78.2%

$-0.48vs$-2.20

Q2 25

No data

Q3 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 10, 2025	—	$-0.12	—	—
Q3 2025	Sep 18, 2025	—	$-1.13	—	—
Q2 2025	May 13, 2025	—	$-0.39	—	—
Q1 2025	Feb 12, 2025	$-2.20	$-0.48	+78.2%	✓ BEAT
Q4 2024	Nov 12, 2024	$-1.70	$-1.20	+29.4%	✓ BEAT
Q3 2024	Sep 19, 2024	$-1.48	$-1.13	+23.6%	✓ BEAT
Q2 2024	May 9, 2024	$-1.38	$-1.37	+0.7%	✓ BEAT
Q1 2024	Feb 13, 2024	$-1.46	$-1.66	-13.7%	✗ MISS
Q4 2023	Nov 9, 2023	$-2.12	$8.46	+499.1%	✓ BEAT
Q4 2023	Oct 27, 2023	—	$-1.51	—	—
Q2 2023	May 11, 2023	$-2.60	$-2.32	+10.8%	✓ BEAT
Q1 2023	Feb 9, 2023	$-3.20	$1.60	+150.0%	✓ BEAT
Q4 2022	Nov 14, 2022	$-2.60	$-2.60	0.0%	= MET
Q3 2022	Sep 8, 2022	$-3.60	$-2.40	+33.3%	✓ BEAT
Q2 2022	May 23, 2022	—	$-0.23	—	—
Q2 2022	May 23, 2022	$-3.40	$-3.40	0.0%	= MET
Q1 2022	Feb 10, 2022	$-3.80	$-2.60	+31.6%	✓ BEAT
Q4 2021	Nov 10, 2021	$-2.60	$-2.60	0.0%	= MET
Q3 2021	Sep 2, 2021	$-0.17	$-0.05	+70.6%	✓ BEAT
Q2 2021	May 6, 2021	$-3.00	$-4.00	-33.3%	✗ MISS